Wellington Management Group LLP Cuts Stake in Moderna, Inc. $MRNA

Key Points

• Wellington Management Group LLP reduced its stake in Moderna, Inc. by 26.0% during the first quarter, leaving it with 2,895,555 shares valued at $82,089,000.
• Despite the stake reduction, several institutional investors including Theleme Partners LLP and Invesco Ltd. increased their positions in Moderna.
• Wall Street analysts have mixed sentiments on Moderna, with 1 Strong Buy, 3 Buy, 16 Hold, and 4 Sell ratings, while the consensus target price is $42.88.

Wellington Management Group LLP trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 26.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,895,555 shares of the company's stock after selling 1,019,537 shares during the period. Wellington Management Group LLP owned about 0.75% of Moderna worth $82,089,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. S Bank Fund Management Ltd bought a new stake in shares of Moderna during the 1st quarter worth $25,000. Itau Unibanco Holding S.A. raised its stake in Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the period. Costello Asset Management INC bought a new stake in Moderna in the 1st quarter valued at about $30,000. Vega Investment Solutions bought a new stake in Moderna in the 4th quarter valued at about $45,000. Finally, Sentry Investment Management LLC bought a new stake in Moderna in the 1st quarter valued at about $31,000. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research reports. Morgan Stanley restated an "equal weight" rating and issued a $32.00 price objective on shares of Moderna in a research note on Friday, August 1st. UBS Group reduced their target price on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Bank of America reduced their target price on Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a report on Tuesday, July 22nd. Finally, William Blair reaffirmed a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, sixteen have assigned a Hold rating and four have given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $42.88.

Moderna Trading Up 1.2%

Shares of NASDAQ MRNA traded up $0.30 during midday trading on Wednesday, hitting $25.03. 15,969,425 shares of the company's stock were exchanged, compared to its average volume of 10,728,063. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $80.56. The company has a market cap of $9.74 billion, a price-to-earnings ratio of -3.33 and a beta of 1.83. The business's fifty day moving average price is $29.15 and its two-hundred day moving average price is $28.97.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. The business had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.Moderna's revenue for the quarter was down 41.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. Equities analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.